Traws Pharma, Inc. (TRAW)
After hours:
| Previous close | 0.6410 |
| Open | 0.6400 |
| Bid | 0.5947 x 100 |
| Ask | 0.6796 x 100 |
| Day's range | 0.6320 - 0.6580 |
| 52-week range | 0.5500 - 1.3300 |
| Volume | |
| Avg. volume | 127,143 |
| Market cap | 16.185M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
GlobeNewswireTraws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and ritonavir-free COVID 19 protease inhibitor NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and ca
- GlobeNewswire
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers Topline Phase 1 data and Phase 2 initiation expected in H2 2024 NEWTOWN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing
Simply Wall St.Traws Pharma Full Year 2023 Earnings: Beats Expectations
Traws Pharma ( NASDAQ:TRAW ) Full Year 2023 Results Key Financial Results Net loss: US$18.9m (flat on FY 2022). US$0.90...
